AstraZeneca and Daiichi Sankyo have reported results from the TROPION-Breast01 Phase III clinical trial of datopotamab ...

A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...

AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

It said the drug did not 'achieve statistical significance' in terms of the survival rates of those suffering from breast ...

Shares of Skye Bioscience gained after the San Diego biopharmaceutical company highlighted the safety of its in-development obesity treatment as compared with rivals. AstraZeneca shares slipped after ...

Analysis of the TROPION-Breast01 study showed that treatment with Dato-DXd did not significantly improve overall survival compared with chemotherapy in HR-positive, HER2-low or -negative breast cancer ...

Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.

Key updates in the health sector have emerged, with AstraZeneca facing disappointment in a breast cancer drug trial. The ...

PARIS: European shares closed higher on Monday as a soft business activity reading strengthened the case for more monetary ...

It is a fictional representation created for illustrative purposes only. AstraZeneca's experimental precision drug, developed ...

EUROPEAN shares closed higher on Monday as a soft business activity reading strengthened the case for more monetary policy ...